



A DAY TO STEP UP THE FIGHT AGAINST MENINGITIS, A RAPIDLY PROGRESSIVE AND POTENTIALLY DEADLY DISEASE

India, 21st April 2016: Meningitis Day is a World day, observed every 24th of April to raise awareness about meningitis, including meningococcal meningitis – a devastating disease that can cause death in 24 hours. ¹

Meningitis is a serious infection that affects the protective layer around the brain and spinal cord.² Meningitis can be caused by viruses, bacteria and fungi.² **One of the common and dangerous forms of meningitis is meningococcal meningitis:** it is caused by the bacterium called *Neisseria Meningitidis* that can also cause bloodstream infection (sepsis).^{2,3}

Meningococcal meningitis is a major cause of illness globally. The annual number of invasive meningococcal disease cases worldwide is estimated to be 1.2 million with 135,000 deaths related to it .⁴

Meningococcal disease may be rapidly progressive and can lead to death in 24 hours.^{1,3} Even with appropriate treatment, 10% of patients who get meningococcal meningitis may die.^{3,9} If the infection progresses to the blood stream, death

An Indian study suggests that in approximately **85% of children suffering from bacterial meningitis, a causative organism is not identified.** ⁵ Despite these challenges in diagnosing meningococcal meningitis (MM), baseline cases have been regularly reported at Government hospitals and private setups in the Country.

As per the National Health Profile report published by the Central Bureau of Health Intelligence, Ministry of Health & Family Welfare, Government of India, there have been more than 27000 cases and more than 1500 death due to Meningococcal Meningitis since 2010 .⁶

India has also seen several outbreaks in the last 30 years in cities such as Delhi (1985-88, 2005-08), Meghalaya (2008-09), Tripura (2009), Gujarat (1985-87), erstwhile Andhra Pradesh (1989) and Madhya Pradesh (1989) to name a few.^{7,8}

rate can be up to 40%.^{3,9} Moreover, about 20% of the survivors may suffer life-long injuries such as amputation of limbs, severe scarring, mental retardation, epilepsy and hearing loss.^{3,9}

The complex aspect of meningitis is that early symptoms could be similar to those of influenza (flu) such as fever, headache, nausea and vomiting, irritability, sore throat or decreased appetit.¹ which makes early diagnosis challenging. Specific symptoms such as hemorrhagic rash, neck pain and stiffness and photophobia are delayed and when they appear, the disease is already at an advanced stage.¹ Late symptoms such as confusion, delirium, seizure or unconsciousness can occur fast and may lead to death.¹ So when it comes to treating this potentially deadly disease, early detection is essential.^{2,10,11}

Meningococcal meningitis affects mainly the young population, and especially children below 5 years of age.^{12,13} Because the bacteria responsible for the disease are transmitted from person-to-person through droplets of respiratory or throat secretions from carriers¹⁴, high-density/crowded populations such as Hajj pilgrims, dormitory students or military recruits are also at increased risk.^{15,16}

Since meningococcal meningitis is an unpredictable disease that can also affect otherwise healthy people in a very short time, speak to your healthcare provider for more information on disease and its prevention.

About Sanofi

Sanofi, a global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi has core strengths in diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and Genzyme. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

Sanofi Pasteur, the vaccines division of Sanofi, provides more than 1 billion doses of vaccine each year, making it possible to immunize more than 500 million people across the globe. A world leader in the vaccine industry, Sanofi Pasteur produces a portfolio of high quality vaccines that match its areas of expertise and meet public health demand. The company's heritage, to create vaccines that protect life, dates back more than a century. Sanofi Pasteur is the largest company entirely dedicated to vaccines. Every day, the company invests more than EUR 1 million in research and development. For more information, please visit: www.sanofipasteur.com.

REFERENCES

- 1) Thompson MJ, Ninis N, Perera R et al. Clinical recognition of meningococcal disease in children and adolescents. *Lancet*. 2006;367:397-403
- 2) Tunkel AR, van de Beeks D, Scheld MW. Acute meningitis. In: Mandell GL, Bennett JE, Dolin R (eds). *Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases*. 7th ed. Philadelphia, Pennsylvania: Churchill Livingstone Elsevier;2010:1189-1229.
- 3) Rosenstein NE, Perkins BA, Stephens DS, Popovic T, Hughes JM. Meningococcal disease. *N Engl J Med*. 2001;344(18):1378-1388
- 4) Jafri RZ, Ali A, Messonnier NE, Tevi-Benissan C, Durrheim D, Eskola J, et al. Global epidemiology of invasive meningococcal disease. *Popul Health Metr*. 2013 Sep 10;11(1):17.
- 5) S.K. Kabra et al. Bacterial Meningitis in India : An IJP Survey. *Indian J Pediatr* 1991; 58 : 505-511

- 6) Adapted from <http://cbhidghs.nic.in/index2.asp?slid=986&sublinkid=1116> accessed on 14 April 2016
- 7) Sinclair D, Preziosi MP, Jacob John T, Greenwood B. The epidemiology of meningococcal disease in India. *Trop Med Int Health*. 2010 Dec;15(12):1421-35.
- 8) Meningococcal Disease: Need to remain alert. *Monthly Newsletter of National Centre for Disease control*. Directorate General of Health Services, Government of India, 2009 Oct-Nov; 13(3)
- 9) Meningococcal vaccines: WHO position paper, November 2011. *Wkly Epidemiol Rec*. 2011;86(47):521-39.
- 10) Stephens DS, Greenwood B, Brandtzaeg P. Epidemic meningitis, meningococcaemia, and Neisseria meningitidis. *Lancet*. 2007;369(9580):2196-2210.
- 11) Raza MM, Heyderman RS. Acute fever and headache - is it meningitis? *J R Coll Physicians Edinb*. 2006;36(3):232-235.
- 12) Background paper on Meningococcal Vaccines. SAGE Working Group. Mar 15, 2011.
http://www.who.int/immunization/sage/1_mening_background_document_v5_3_apr_2011.pdf Accessed on 16.01.2015
- 13) Memish Z, Al Hakeem R, Al Neel O, Danis K, Jasir A, Eibach D. Laboratory-confirmed invasive meningococcal disease: effect of the Hajj vaccination policy, Saudi Arabia, 1995 to 2011. *Euro Surveill*. 2013;18(37). pii: 20581.
- 14) Meningococcal meningitis. Fact sheet N°141. February 2015. Available from <http://www.who.int/mediacentre/factsheets/fs141/en/>, accessed on 18.02.2015
- 15) Pollard AJ. Meningococcal infections. In: Longo DL, Fauci AS, Kasper DL, et al, eds. *Harrison's Principles of Internal Medicine*. 18th ed. New York, NY: McGraw-Hill; 2012; chapter 143.
- 16) MacNeil J, Cohn A. Meningococcal disease. In: Roush SW, McIntyre L, Baldy LM, eds. *Manual for the Surveillance of Vaccine-Preventable Diseases*. 5th ed. Atlanta, GA: Centers for Disease Control and Prevention; 2012. 18 <http://www.cdc.gov/vaccines/pubs/surv-manual/chpt08-mening.pdf>. Accessed January 3, 2014.
- 17) WHO. WHO vaccine-preventable diseases: monitoring system. 2015 global summary. Available at: http://apps.who.int/immunization_monitoring/globalsummary/schedules Accessed on: 17/03/2016

Forward Looking Statements

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words "expects", "anticipates", "believes", "intends", "estimates", "plans" and similar expressions. Although Sanofi's management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the absence of guarantee that the product candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, the Group's ability to benefit from external growth opportunities, trends in exchange rates and prevailing interest rates, the impact of cost containment initiatives and subsequent changes thereto, the average number of shares outstanding as well as those discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in Sanofi's annual report on Form 20-F for the year ended December 31, 2015. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.

India Media Relations

Sanofi

Aparna Thomas

T. +91-22-28-27-81-69

aparna.thomas@sanofi.com

www.sanofi.com